Chinese pharmaceutical firm Jiangsu Atom Bioscience & Pharmaceutical has raised over 300 million yuan ($47.2 million) in a Series C round of financing led by Beijing-based Kingray Capital, a state-backed firm that invests in Chinese yuan.